Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)

21,26 +0,26 (+1,24%) Alla chiusura: 03:04PM CST

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

East Lake Hi-Tech Development Zone
No.388, Gaoxin 2nd Road
Wuhan 430074
China
86 27 6552 3649
https://www.mdeasydiagnosis.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 1.547

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Chen Li Li	Chairman & GM	N/D	N/D	1974
Ms. Wang Ying	Vice Chairman & Deputy GM	N/D	N/D	1974
Mr. Guohui Zhou	Financial Manager	N/D	N/D	1984
Mr. Rui Wang	Deputy GM & Board Secretary	N/D	N/D	1978

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CNY.

Descrizione

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer. The company also provides emergency and critical illness information solutions, including software, hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular and cerebrovascular diseases, infectious diseases, kidney diseases, diabetes, infectious diseases, prenatal and postnatal care, health examination, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection, etc. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.

Governance aziendale

L'ISS Governance QualityScore di Wuhan Easy Diagnosis Biomedicine Co.,Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.